VT301 / VT BIO - LARVOL DELTA

A preclinical and phase I clinical study of ex vivo-expanded amyloid beta-specific human regulatory T cells in Alzheimer's disease. (PubMed, Biomed Pharmacother) - P1 | "This study suggests that hTregs may modulate Alzheimer's disease pathology by suppressing neuroinflammation, while VT301 shows promise as a safe treatment option. However, further research is necessary to confirm its clinical efficacy and optimize treatment strategies."

Journal • P1 data • Preclinical • Alzheimer's Disease • CNS Disorders • Inflammation

VTbio “Clinical treatment for cell therapy VT301 is cruising…to be completed within this year” [Google translation] (Health Korea News) - "VT Bio...announced...that the phase 1 clinical trial of VT301, a cell therapy, currently underway at Seoul National University Hospital is underway as planned....'The domestic phase 1 clinical trial is scheduled to be completed in the second half of the year, and based on the results, we will proceed with the next phase clinical trial within the first half of 2023'....'We have secured the conditions for the cryoprotectant, and based on this, we will apply for a new international patent in the second half of the year...'"

New trial • Patent • Trial completion date • Trial status • Alzheimer's Disease • CNS Disorders

A NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE USING AMYLOID ΒETA-SPECIFIC HUMAN REGULATORY T CELLS TO CONTROL MICROGLIA ACTIVATION IN 3XTG MOUSE BRAIN. (ADPD 2022) - "Here we confirm whether expanded amyloid-beta (Aβ)-specific Tregs with bvPLA2 in vitro (designated Ag-hTreg, VT301) exhibits efficacy as a therapeutic agent for neuro-inflammation. Therefore, our finding opens up the possibility of the clinical application using Treg as a cell therapy for Alzheimer's disease or microglia-related neuroinflammatory diseases."

Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Immunology • Inflammation • Psychiatry • CD4 • FOXP3 • IL2RA

A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: VTBIO Co. LTD

Clinical • New P1 trial • Alzheimer's Disease • CNS Disorders

A Safety and Tolerability Study of GB301 (clinicaltrials.gov) - P1/2; N=20; Not yet recruiting; Sponsor: GMP BIO Co., LTD.; Trial completion date: Jan 2020 ➔ Dec 2021; Initiation date: Jun 2019 ➔ Dec 2019; Trial primary completion date: Dec 2019 ➔ Dec 2020

Clinical • Trial completion date • Trial initiation date • Trial primary completion date